Efavirenz or nevirapine in three-drug combination therapy with two nucleoside or nucleotide-reverse transcriptase inhibitors for initial treatment of HIV infection in antiretroviral-naïve individuals

@inproceedings{Mbuagbaw2016EfavirenzON,
  title={Efavirenz or nevirapine in three-drug combination therapy with two nucleoside or nucleotide-reverse transcriptase inhibitors for initial treatment of HIV infection in antiretroviral-na{\"i}ve individuals},
  author={Lawrence Tanyi Mbuagbaw and Sara Mursleen and James H Irlam and Alicen B Spaulding and George Rutherford and Nandi Siegfried},
  booktitle={The Cochrane database of systematic reviews},
  year={2016}
}
BACKGROUND The advent of highly active antiretroviral therapy (ART) has reduced the morbidity and mortality due to HIV infection. The World Health Organization (WHO) ART guidelines focus on three classes of antiretroviral drugs, namely nucleoside or nucleotide reverse transcriptase inhibitors (NRTI), non-nucleoside reverse transcriptase inhibitors (NNRTI) and protease inhibitors. Two of the most common medications given as first-line treatment are the NNRTIs, efavirenz (EFV) and nevirapine (NVP… CONTINUE READING
BETA
Tweets
This paper has been referenced on Twitter 3 times. VIEW TWEETS

References

Publications referenced by this paper.
SHOWING 1-10 OF 12 REFERENCES

Amended We amended the sources

  • Event Description
  • 2011
1 Excerpt

Berg-Wolf 2008 (Continued) Risk of bias Bias

  • van den
  • 2008

editor(s). Cochrane Handbook for Systematic Reviews of Interventions

  • JPT Higgins 2008 Higgins, S Green, JPT editor. In Higgins
  • 2008

Comparison of plasma HIV-1 RNA, CD4 cell count, and CD38 expression on CD8 T cells as predictors of progression to AIDS and CD4 cell decline

  • J Mellors 2007 Mellors, J Margolick, J Phair, C Rinaldo, R Detels, L Jaconson
  • 2007

Predictive value of plasma HIV RNA levels for rate of CD4 decline and clinical disease progression

  • B Lau 2007 Lau, S Gange, G Kirk, S Mehta, B Merriman, R. Moore
  • 14th Conference on Retroviruses and Opportunistic…
  • 2007

Characteristics of included studies [ordered by study ID

  • 2004

Considerations in the choice of protease inhibitor-sparing regimens in initial therapy for HIV-1 infection

  • GJ Moyle2000Moyle
  • Current Opinion in Infectious Diseases
  • 2000

Similar Papers

Loading similar papers…